Drugs / Zeprumetostat
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07692529 | Aug 2026 → Dec 2027 expected | T-cell large granular lymphocyte leukemia | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07082803 | Jun 2025 → Sep 2030 expected | non-Hodgkin lymphoma | Treeline Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07706959 | Jul 2026 → Jan 2028 expected | peripheral T-cell lymphoma, not otherwise specified | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07643805 | Jun 2026 → Jan 2028 expected | diffuse large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07502768 | Apr 2026 → Dec 2027 expected | extranodal nasal NK/T cell lymphoma, mature T-cell and NK-cell non-Hodgkin lymphoma | Rong Tao | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07493330 | Mar 2026 → Dec 2029 expected | refractory malignant neoplasm | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07339527 | Jan 2026 → Jan 2028 expected | mature T-cell and NK-cell non-Hodgkin lymphoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07854639 | Oct 2026 → Dec 2027 expected | primary cutaneous T-cell lymphoma | Peking University First Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07555470 | Apr 2026 → Dec 2029 expected | follicular lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07372352 | Jan 2026 → Jan 2028 expected | peripheral T-cell lymphoma, not otherwise specified | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT07339553 | Jan 2026 → Jan 2029 expected | ovarian carcinoma | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-15 | Jiangsu HengRui Medicine Co., Ltd. | Results 2026 EHA｜恒瑞创新药海曲泊帕、立康可泮、泽美妥司他等10余项血液学最新研究成果亮相 hengrui.com ↗
截至2026年1月28日，10例患者可评估疗效（4mg组6例，8mg组4例），最佳ORR为40.0%（4/10），DCR为80.0%（8/10），其中CR 2例，PR 2例。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-15 | Jiangsu HengRui Medicine Co., Ltd. | 2026 EHA｜恒瑞创新药海曲泊帕、立康可泮、泽美妥司他等10余项血液学最新研究成果亮相 hengrui.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zeprumetostat | “Phase 2: Zeprumetostat Tablets in Combination with Fuzuloparib Dose: Zeprumetostat Tablets 250 mg, bid, po, Fuzuloparib 100 mg, bid, po.” NCT07339553 ↗10“Single-Arm Clinical Study of Zeprumetostat in Combination with Glofitamab + GemOx in Patients with Relapsed/ Refractory DLBCL” NCT07643805 ↗ |
| Known as | SHR2554 | “Zeprumetostat (SHR2554), an oral EZH2 inhibitor, administered twice daily.” NCT07502768 ↗ |
| Known as | TLN-254 | “Drug: zeprumetostat (TLN-254)” NCT07082803 ↗ |
| Action | Inhibit | “EZH2 inhibitor Zeprumetostat” NCT07339527 ↗ |
| Modality | Small molecule | — CHEMBL5939817 ↗ |
| Route | Oral | “350mg, po, bid” NCT07339527 ↗ |
| Target | EZH2 | “EZH2 inhibitor Zeprumetostat” NCT07339527 ↗ |